Gemini Therapeutics, Inc. GMTX
We take great care to ensure that the data presented and summarized in this overview for Gemini Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding GMTX
View allLatest Institutional Activity in GMTX
Top Purchases
Top Sells
About GMTX
Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Insider Transactions at GMTX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 16
2024
|
John D Quisel Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
12,791
-3.94%
|
$831,415
$65.95 P/Share
|
|
Dec 16
2024
|
John D Quisel Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,791
+13.1%
|
$12,791
$1.01 P/Share
|
|
Dec 02
2024
|
William Richard White |
SELL
Open market or private sale
|
Direct |
1,957
-64.06%
|
$125,248
$64.47 P/Share
|
|
Dec 02
2024
|
William Richard White |
BUY
Exercise of conversion of derivative security
|
Direct |
1,957
+29.66%
|
$11,742
$6.26 P/Share
|
|
Nov 25
2024
|
William Jacob Savage Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
14,183
-9.41%
|
$921,895
$65.93 P/Share
|
|
Nov 25
2024
|
William Jacob Savage Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
14,183
+12.19%
|
$156,013
$11.68 P/Share
|
|
Nov 15
2024
|
William Jacob Savage Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
9,158
-6.33%
|
$549,480
$60.27 P/Share
|
|
Nov 15
2024
|
William Jacob Savage Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,158
+15.6%
|
$82,422
$9.86 P/Share
|
|
Nov 04
2024
|
William Richard White |
SELL
Open market or private sale
|
Direct |
7,136
-62.54%
|
$413,888
$58.26 P/Share
|
|
Nov 04
2024
|
William Richard White |
BUY
Exercise of conversion of derivative security
|
Direct |
7,136
+50.0%
|
$321,120
$45.69 P/Share
|
|
Nov 01
2024
|
William Richard White |
SELL
Open market or private sale
|
Direct |
201
-67.91%
|
$9,246
$46.22 P/Share
|
|
Nov 01
2024
|
William Richard White |
BUY
Exercise of conversion of derivative security
|
Direct |
201
+50.0%
|
$1,809
$9.86 P/Share
|
|
Oct 01
2024
|
William Richard White |
SELL
Open market or private sale
|
Direct |
201
-44.59%
|
$10,050
$50.88 P/Share
|
|
Oct 01
2024
|
William Richard White |
BUY
Exercise of conversion of derivative security
|
Direct |
201
+50.0%
|
$1,809
$9.86 P/Share
|
|
Sep 16
2024
|
William Jacob Savage Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,500
-3.58%
|
$70,500
$47.41 P/Share
|
|
Sep 03
2024
|
William Richard White |
SELL
Open market or private sale
|
Direct |
1,957
-86.98%
|
$97,850
$50.89 P/Share
|
|
Sep 03
2024
|
William Richard White |
BUY
Exercise of conversion of derivative security
|
Direct |
1,957
+48.65%
|
$11,742
$6.26 P/Share
|
|
Sep 03
2024
|
William Jacob Savage Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,500
-3.46%
|
$75,000
$50.59 P/Share
|
|
Aug 01
2024
|
William Richard White |
SELL
Open market or private sale
|
Direct |
201
-85.82%
|
$8,643
$43.6 P/Share
|
|
Aug 01
2024
|
William Richard White |
BUY
Exercise of conversion of derivative security
|
Direct |
201
+50.0%
|
$1,809
$9.86 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 389K shares |
|---|---|
| Grant, award, or other acquisition | 625K shares |
| Exercise of conversion of derivative security | 83.3K shares |
| Open market or private sale | 404K shares |
|---|